LPTX   $0.39  3.13% Market Closed

Leap Therapeutics Inc
Last Events:

2023-05-04 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: main and signal line crossing.

2023-05-04 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-05-04 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-05-04 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-04-29 Signal in Stochastic changed from bearish weakening to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-04-28 Trend pattern changed from симметричный треугольник to расходящийся клин с наклоном вниз.

2023-04-28 Signal in Stochastic changed from bullish reversal to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: main and signal line crossing.

2023-04-28 Signal in MACD changed from bearish to bullish reversal. Oscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.


Current temperature: 2.40
ST: 0, Cor:

50-50 Year Forecast
Low with 51% probability: 0.33
Target: 2.50
High with 48% probability: 0.95
Analyst Recommendations:
Number of estimates 5
Target Price Mean 2.50
Mean unverified/preliminary 2.50 / 2.50
Target Price Low / High 2.00 / 3.00
Median / STD DEV 2.50 / 0.50
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd Sell - -
stoch Sell - -
ma20 Sell Sell Sell
ma50 Sell - -
ma100 Sell Sell -
Candlestick PatternMay 3, 2023 Three Stars -
ISIN US52187K1016
ceo Mr. Douglas E. Onsi J.D.
Website https://www.leaptx.com
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.